(redirected from Bypass Angioplasty Revascularization Investigation)
Also found in: Medical.
BARIBypass Angioplasty Revascularization Investigation (clinical trial)
BARIBangladesh Agricultural Research Institute (Joydebpur, Bangladesh)
BARIBusch Agricultural Resources, Inc. (various locations)
BARIBritish Archaeological Reports International Series
BARIBalloon Angioplasty Revascularization Investigation (cardiology)
BARIBihar Agricultural Research Institute (India)
References in periodicals archive ?
27] The Bypass Angioplasty Revascularization Investigation (BARI) study was the first trial summarized in a meta-analysis of 7794 patients, indicating the different mortality rates between CABG and PCI,[28] and demonstrated that CABG was superior over PCI in diabetic patients.
To examine the possible relationship between elevated troponin T and adverse CV outcomes in patients who had both stable ischemic heart disease and diabetes, the investigators performed a post hoc analysis of data gathered in the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) clinical trial, which compared outcomes between patients who underwent preventive percutaneous coronary intervention or coronary artery bypass grafting plus intensive medical therapy against those who received intensive medical therapy alone.
Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators.
In addition, the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D), which also studied two glucose-lowering strategies, found no difference in outcome whether the patients received insulin-providing or insulin-sensitizing therapy.